
Zymeworks Inc
ZYMEHealthcare|Biotechnology|USA
$25.88
-1.19 (-4.40%)
Tangible Book
$2.04
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
314.54,
220.72,
240.12,
342.19,
469.59
],
"ebit_estimate": [
98.44,
87.99,
48.5,
103.76,
122.7
],
"ebitda_estimate": [
75.47,
112.06,
102.71,
null,
null
],
"net_income_estimate": [
89.23,
84.2,
47.71,
83.56,
94.33
],
"per_share_eps_estimate": [
1.54,
0.69,
0.45,
1.14,
1.12
],
"eps_nri_estimate": [
1.11,
0.48,
0.54,
1.01,
1.12
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
124.87,
93.63,
49.92,
89.65,
100.93
],
"operating_cash_flow_per_share_estimate": [
1.61,
-0.7,
null,
null,
null
],
"roa_estimate": [
15.9,
-11.9,
null,
null,
null
],
"roe_estimate": [
26.66,
-20.4,
16.55,
null,
null
],
"gross_margin_estimate": [
98.9,
91.5,
100,
100,
100
],
"operating_cash_flow_estimate": [
120.26,
-52.29,
null,
null,
null
],
"pettm_estimate": [
16.85,
37.51,
57.64,
22.8,
23.07
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
20.82,
189.06,
131.66,
79.14,
80.05,
102.56,
68.1,
null
],
"ebit_estimate": [
-31.98,
130.49,
65.48,
-16.36,
62.09,
104.74,
-7.53,
null
],
"ebitda_estimate": [
-44.37,
192.25,
-25.93,
null,
null,
null,
null,
null
],
"net_income_estimate": [
-30.24,
124.51,
59,
-21.86,
40.56,
71.55,
-14.01,
null
],
"per_share_eps_estimate": [
-0.4,
1.51,
0.96,
-0.31,
0.58,
1.02,
-0.2,
-0.28
],
"eps_nri_estimate": [
-0.44,
1.86,
0.56,
0.3,
0.23,
0.45,
-0.3,
-0.28
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-30.73,
130.44,
66.06,
-21.86,
55.56,
98.01,
-14.01,
null
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
-105.87,
340.04,
-40.26,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
100,
100,
100,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
14.65,
9.44,
11.48,
23.74,
23.07,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}